Literature DB >> 9203655

Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus.

D C Powers1, J E McElhaney, O A Florendo, M C Manning, C M Upshaw, D W Bentley, B E Wilkinson.   

Abstract

Adults were immunized with either baculovirus-expressed, purified recombinant hemagglutinin (rHA) from influenza A/Beijing/32/92 (H3N2) virus or saline placebo and evaluated for humoral and in vitro cellular immune responses. Compared with responses in placebo recipients, vaccinees had greater postvaccination H3(Beijing/32) HA (H3)-specific lymphoproliferation and interleukin (IL)-2, IL-10, and interferon-gamma (IFN-gamma) production. Mean increases in the production of IL-10 (> or = 20-fold) and IL-2 (10-fold) were relatively greater than that of IFN-gamma (4-fold) or IL-4 (no change). Serum H3 antibodies were induced in 80% of rHA recipients, and the rise in antibody titer was significantly correlated with changes in IL-2, IL-10, and IFN-gamma concentrations. Vaccination with rHA only minimally enhanced anti-influenza virus cytotoxic T lymphocyte activity. These data demonstrate that rHA immunization of adults elicits a significant recall response by memory B and T lymphocytes and suggest that the cytokine response to vaccination has a T helper cell type 0-like profile.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203655     DOI: 10.1093/infdis/175.2.342

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

Review 2.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

Review 3.  Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

Review 4.  Advances in novel influenza vaccines: a patent review.

Authors:  Jae-Min Song
Journal:  J Microbiol       Date:  2016-05-27       Impact factor: 3.422

5.  Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans.

Authors:  Xin Zhou; Janet E McElhaney
Journal:  Vaccine       Date:  2011-03-03       Impact factor: 3.641

6.  Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

Authors:  Surender Khurana; Swati Verma; Nitin Verma; Corey J Crevar; Donald M Carter; Jody Manischewitz; Lisa R King; Ted M Ross; Hana Golding
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

Review 7.  Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Authors:  Aseem Pandey; Neetu Singh; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Hum Vaccin       Date:  2010-02-24

8.  Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.

Authors:  Alfonso García-Piñeres; Allan Hildesheim; Lori Dodd; Troy J Kemp; Marcus Williams; Clayton Harro; Douglas R Lowy; John T Schiller; Ligia A Pinto
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

9.  Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus.

Authors:  Chih-Jen Wei; Ling Xu; Wing-Pui Kong; Wei Shi; Kevin Canis; James Stevens; Zhi-Yong Yang; Anne Dell; Stuart M Haslam; Ian A Wilson; Gary J Nabel
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

10.  Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans.

Authors:  Anne Chauvat; Nadine Benhamouda; Alain Gey; Francois M Lemoine; Staffan Paulie; Fabrice Carrat; Marie-Lise Gougeon; Flore Rozenberg; Anne Krivine; Mustapha Cherai; Paul Lehmann; Françoise Quintin-Colonna; Odile Launay; Eric Tartour
Journal:  Hum Vaccin Immunother       Date:  2013-10-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.